When a Trial 'Fails' but Patients Are Satisfied: Absent Patient Input in End Point Selection for a Nipple Reconstruction Device
Source
Medical Device Innovation Consortium
Link
Maximizing Patient Input in the Design and Development of Medical Device Clinical Trials
Description of Case Study
In a clinical study of the Biodesign Nipple Reconstruction Cylinder, an implantable device used for nipple reconstruction in postmastectomy patients, the primary end point was maintenance of nipple projection length over 12 months—a measure chosen, per the study authors, largely to allow comparison with other similar devices. Patient satisfaction was collected only as a secondary measure, via questionnaire, and patients were not engaged in selecting or weighting the trial’s end points during protocol design. The study did not meet its primary end point (patients did not maintain the prespecified 50 percent of initial projection length at 12 months). However, 93 percent of patients reported being “pleased” or “very pleased” with the outcome, and 98 percent said they would recommend the procedure to other women. This case demonstrates the potential consequences of finalizing a medical device trial’s end points without patient input on what constitutes a meaningful, patient-relevant outcome.
Quick Facts Organization name: Cook Biodesign® |
Product Type(s)
medical device:
- implantable device
- innovative device
Product Medical Specialty Area(s)
- general and plastic surgery
Stakeholders
- medtech company: internal clinical affairs/research and development teams
- regulators
Methods and Sources of Patient Input
- clinical outcome assessments (patient-reported outcomes, clinician-reported outcomes, observer- reported outcomes)
- customer satisfaction data
Impact of Limited, Absent, or Late Patient Engagement
This case illustrates the cost of not engaging patients early in trial design:
- Misaligned primary end point: Because patients were not engaged in defining what a successful outcome looked like, the trial’s primary end point (nipple projection) did not reflect what patients valued most. Despite high patient satisfaction, the trial was deemed to have failed based on its primary end point.
- Missed opportunity to demonstrate real-world success: The mismatch between the clinical outcome (end point failure) and the patient outcome (high satisfaction) meant that the trial could not be used to make a compelling case for the device’s value to patients, even though patients found it beneficial.
- Less relevant evidence for decision-making: The disconnect illustrates how a lack of early patient engagement can produce evidence that is less useful for regulators, clinicians, and patients, even when the underlying therapy appears to deliver real patient benefit.
Lessons Learned
- Engage patients before finalizing end points: Had patients been consulted during trial design, the primary end point might have been selected or weighted differently to better reflect patient-defined success.
- Align clinical and patient-centered end points: Designing a trial around a technical end point without first confirming it reflects what matters most to patients could risk a trial being characterized as a failure (if the technical end point fails) even if patient satisfaction data provide evidence of real patient benefit.